“Evaluating Fluoxetine’s Growth-Inhibitory Impact on Clinical Isolates of Enteric Bacteria: Harnessing Repurposing Potential” (2023) Microbiological & Immunological Communications, 2(2), pp. 89–96. doi:10.55627/mic.002.02.0454.